[Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
Faecal iron excretion during continuous subcutaneous deferoxamine infusion was measured by flameless atom-absorption spectral photometry in 21 patients with homozygous ss-thalassaemia and one patient with Blackfan-Diamond anaemia. Taking into account faecal and urinary iron excretion, more iron was eliminated than was taken up during transfusion and by intestinal absorption. Urine contained 37.9%, faeces 62.1% of the amount of iron eliminated.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005243:Feces / Q000032:analysis*; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous / Q000379:methods; D007501:Iron / Q000032:analysis*; D008297:Male; D012646:Self Administration; D013789:Thalassemia / Q000150:complications
D007501:Iron; D003676:Deferoxamine
Deferoxamin bei Hämosiderose. Fäkale Eisenausscheidung während kontinuierlicher subkutaner Infusionen.